Suppr超能文献

微小RNA替代疗法的前景。

The promise of microRNA replacement therapy.

作者信息

Bader Andreas G, Brown David, Winkler Matthew

机构信息

Mirna Therapeutics, Inc. and Asuragen, Inc., Austin, TX 78744, USA.

出版信息

Cancer Res. 2010 Sep 15;70(18):7027-30. doi: 10.1158/0008-5472.CAN-10-2010. Epub 2010 Aug 31.

Abstract

MicroRNAs (miRNA), a class of natural RNA-interfering agents, have recently been identified as attractive targets for therapeutic intervention. The rationale for developing miRNA therapeutics is based on the premise that aberrantly expressed miRNAs play key roles in the development of human disease, and that correcting these miRNA deficiencies by either antagonizing or restoring miRNA function may provide a therapeutic benefit. Although miRNA antagonists are conceptually similar to other inhibitory therapies, restoring the function of a miRNA by miRNA replacement is a less well characterized approach. Here, we discuss the specific properties of miRNA replacement and review recent examples that explored the therapeutic delivery of miRNA mimics in animal models of cancer.

摘要

微小RNA(miRNA)是一类天然的RNA干扰因子,最近已被确定为具有吸引力的治疗干预靶点。开发miRNA疗法的基本原理基于这样一个前提,即异常表达的miRNA在人类疾病的发展中起关键作用,并且通过拮抗或恢复miRNA功能来纠正这些miRNA缺陷可能会带来治疗益处。虽然miRNA拮抗剂在概念上与其他抑制性疗法相似,但通过miRNA替代来恢复miRNA的功能是一种特征尚不明确的方法。在这里,我们讨论miRNA替代的具体特性,并回顾最近在癌症动物模型中探索miRNA模拟物治疗递送的实例。

相似文献

1
The promise of microRNA replacement therapy.
Cancer Res. 2010 Sep 15;70(18):7027-30. doi: 10.1158/0008-5472.CAN-10-2010. Epub 2010 Aug 31.
3
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17.
4
MicroRNA replacement therapy in cancer.
J Cell Physiol. 2019 Aug;234(8):12369-12384. doi: 10.1002/jcp.28058. Epub 2019 Jan 3.
5
Treating cancer with microRNA replacement therapy: A literature review.
J Cell Physiol. 2018 Aug;233(8):5574-5588. doi: 10.1002/jcp.26514. Epub 2018 Mar 9.
6
microRNA inhibitors: Natural and artificial sequestration of microRNA.
Cancer Lett. 2017 Oct 28;407:139-147. doi: 10.1016/j.canlet.2017.05.025. Epub 2017 Jun 8.
7
Therapeutic microRNA strategies in human cancer.
AAPS J. 2009 Dec;11(4):747-57. doi: 10.1208/s12248-009-9145-9. Epub 2009 Oct 29.
8
MicroRNA Therapeutics: the Next Magic Bullet?
Mini Rev Med Chem. 2015;15(6):467-74. doi: 10.2174/1389557515666150324123208.
9
MicroRNA silencing in primates: towards development of novel therapeutics.
Cancer Res. 2009 Jan 15;69(2):393-5. doi: 10.1158/0008-5472.CAN-08-2749.
10
Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.
Int J Mol Sci. 2017 Dec 27;19(1):65. doi: 10.3390/ijms19010065.

引用本文的文献

2
Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Cancers (Basel). 2025 Jul 24;17(15):2453. doi: 10.3390/cancers17152453.
3
MicroRNA-Based Delivery Systems for Chronic Neuropathic Pain Treatment in Dorsal Root Ganglion.
Pharmaceutics. 2025 Jul 18;17(7):930. doi: 10.3390/pharmaceutics17070930.
4
The Role of Non-Coding RNAs in ALS.
Genes (Basel). 2025 May 23;16(6):623. doi: 10.3390/genes16060623.
5
The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications.
Noncoding RNA Res. 2025 May 23;14:65-95. doi: 10.1016/j.ncrna.2025.05.012. eCollection 2025 Oct.
6
Role of miRNA in adult ocular tumorigenesis.
Front Mol Biosci. 2025 May 8;12:1459761. doi: 10.3389/fmolb.2025.1459761. eCollection 2025.
7
hsa-miR-5688 inhibits FOXC1-OCT4/SOX2 feedforward loop that drives chemoresistance in breast cancer stem cells.
Mol Ther Oncol. 2025 Apr 8;33(2):200982. doi: 10.1016/j.omton.2025.200982. eCollection 2025 Jun 18.
8
Targeting Regulatory Noncoding RNAs in Human Cancer: The State of the Art in Clinical Trials.
Pharmaceutics. 2025 Apr 4;17(4):471. doi: 10.3390/pharmaceutics17040471.
9
MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications.
J Exp Clin Cancer Res. 2025 Apr 21;44(1):126. doi: 10.1186/s13046-025-03391-x.
10
Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.
Noncoding RNA. 2025 Feb 13;11(1):16. doi: 10.3390/ncrna11010016.

本文引用的文献

1
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Cancer Res. 2010 Jul 15;70(14):5923-30. doi: 10.1158/0008-5472.CAN-10-0655. Epub 2010 Jun 22.
2
Regression of murine lung tumors by the let-7 microRNA.
Oncogene. 2010 Mar 18;29(11):1580-7. doi: 10.1038/onc.2009.445. Epub 2009 Dec 7.
4
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.
PLoS One. 2009 Aug 28;4(8):e6816. doi: 10.1371/journal.pone.0006816.
5
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.
6
Cancer complexity slows quest for cure.
Nature. 2008 Sep 11;455(7210):148. doi: 10.1038/455148a.
7
The let-7 microRNA reduces tumor growth in mouse models of lung cancer.
Cell Cycle. 2008 Mar 15;7(6):759-64. doi: 10.4161/cc.7.6.5834. Epub 2008 Mar 3.
8
Suppression of non-small cell lung tumor development by the let-7 microRNA family.
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8. doi: 10.1073/pnas.0712321105. Epub 2008 Feb 28.
9
let-7 regulates self renewal and tumorigenicity of breast cancer cells.
Cell. 2007 Dec 14;131(6):1109-23. doi: 10.1016/j.cell.2007.10.054.
10
microRNAs join the p53 network--another piece in the tumour-suppression puzzle.
Nat Rev Cancer. 2007 Nov;7(11):819-22. doi: 10.1038/nrc2232.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验